Connect with us

Cannabis News

Wisconsin GOP Assembly Speaker Hopes For ‘Consensus’ On Medical Marijuana, But Says New Senate Bill Is ‘Too Broad’

Published

7 months ago

on

Wisconsin’s GOP Assembly The Legitius pointed out to legislators in the state “I can find agreement to legalize medical marijuana. But he added that The new Cannabis Bill presented Billpart of his Leadership in the Senate It is “unlikely” to exceed his chamber “is a broad and extensive way.”

“I’ve tried for five or six years” Loudspeakers Robin Vos (R) I said speaker on a conversation with Wisn-Tv on Sunday. “The idea that we will have medicine dispensers in all cities around the state, I don’t know where most people are.”

Last year, VOS restricted a medical channel bill Asked a limited program through state discourses.

“So we tried to be a much more limited version,” Let’s look at five or six discharge Americans (and) to help people who are not actually sick of diagnosis, “he said in the new interview.

But the model of the state had a controversial among his Republican colleagues, and suddenly stopped. Now, Vos last week’s President Mary Felzkowski (R) and GOP Legislature will be emerging concerns about new legislation included in other traditional protection systems.

“I still think it’s like trying to find agreement, but it’s like a version that was released, people worrying that people will bring leisure marijuana.” “I don’t want that.”

The speaker said it was “unlikely” that the Senate bills could be cleaned enough to clean the assembly.




“There is a whole group of Republic I understand, because they think it will be out of the recreation marijuana, that it would be horrible for Wisconsin,” he said. “There is another group that wants to legalize marijuana, and they are democrats, so they don’t want to be a real restriction.”

“So it’s very difficult to try to find the central consensus, and that’s why I thought it was a very scale, aimed at people who were really sick and poor. However, it will not be seen in a scenario.”

Asked the new bill of Senate boss, vos celurbill “Probably” should not be reached.

Last week, Felzkowski (R), previously supported another project in Cannabis Bill. Patrick testin (r) Sen. R) presented a new measure.

The text of the proposal was not immediately available, but Felzkowski would have previously invoices Doctors allow patients to issue medical cannabis recommendations One of eight conditions, including cancer, seizure disorders, traumatic stress cover and multiple sclerosis.

Legislation was relatively restrictive because the prohibited marijuana products were banned and did not raise their patients for personal authorization. Patients could only get cannabis preparations for oil, tablets, inkjet or topical.

“Someone who suffers a serious health condition should not be chance to travel to another state or break the law, try alternative medicine for relief,” said Felzkowski in a press release.

“This legislation is about providing a chronic disease to our friends, family members and neighbors, the freedom to study another chance with the doctor,” he said. “It is also possible for our small business businesses to participate in this market with reasonable regulations for making and selling products, all protecting public security.”

Session 2025 was launched, Senate’s leader said He hopes to have a dialogue in legislature on legalization of medical marijuana This year, however, the speaker of the assembly, he still imagined “obstacles”.

Meanwhile, the Republican candidate for governor Wisconsin said in July “Considering different options” was open “marijuana when they use doctors or adults In the state, even if he has given few ways to the specification so far.

Democratic side, today’s Gov. Tony never (d), which supports legalization of cannabis, is not again looking for elections. But he said in June When his party can take control of the legislature, the state may legalize the “Eventually” marijuana Residents should not go to the side of Illinois to visit adult use in the market.

In June, a survey of Marquette Law School discovered Two wisconsin voters help legalize marijuana.

The survey found the support for cannabis reform, usually since the organization has first started, since the continued public opinion of legalization in 2013, 67% of the voters protect the policy change. That’s 17% higher than the results of 2013.

Democrats are the best legalizing cannabis, in 88 percent, and then independent (79 percent). However, most Republicans (56 percent) said they are against the legalization of adults.

Emphasize the importance of the party control, the Senate of the State Senate Republic and the Assembly rejected another attempt to legalize marijuana this summer, Defeating corrections of the budget legislation that would end the State Prohibition And he established new programs for cannabis medical and recreation programs.

Ever This policy attempted to change as part of his budget requests-And democratic leaders have also been promoted to reform.

Republicans in legislature Also cut the provisions of marijuana from the state budget proposal in Mayas they did in past sessions.

Although Republicans move from the legalization of the budget legislation, Party leaders recently recognized the debate about medical marijuana legalization “that will not leave” And this session is expected to be resolved.

–
Marijuana is a moment Monitoring of hundreds of cannabis, psychedelic and drug policy invoices This year’s state legislatures and congresses. Patreon supporters At least $ 25 / monthly enter our interactive maps, graphs and listening to the listening calendar, so they do not lose development.

Learn more about us Marihuana Bill Tracker and become Assistant Patreon to get access.
–

“I don’t think anyone marijuana and thc products are not believed that marijuana and thc products are not available when they are available in line lines, so I think we need to get to an answer about this,” the leader of the General Assembly. Tyler said August (r) in February. “I hope we can.”

“We will call the marijuana doctor if we have to be treated as pharmacy. But the marijuana discussion will be something that will leave,” Dan Feyen (R), the Majority Assistant said at the time. “Margins are more closely.”

Provided his intention as long as he previews January into Marijuana LegalizationWhile the residents of the State must propose new laws, putting binding questions about linking chanabis reform, being able to enjoy the support of Bipartis, has repeatedly refused the GOP-controlled legislature.

Before, in 2022, the governor signed a corrective order with a specific goal of calling a special legislature give people right to dispose of citizen initiativesElectrations of cannabis to decide to collect expectations among the advocates that the voters could decide. The GOP legislature did not take the proposal, however.

He never said in December Marijuana reform is one of the key priorities that the State should move forward In the 2025 session, the legislator works with a quote surplus.

Notes after making a The survey was found to be welcome by reform voters in the countryside of state. Almost two-thirds (65 percent) said they accept the legalization of cannons.

In the end, the governor said that the “promising” was partly that the November 2024 election would bring democratic control of the legislature Argued that he would locate the statue to legalize cannabis.

“We worked hard in the last five years, several budgets, to happen,” he said at the time. “I know we are surrounded by states of recreation marijuana, and we will continue to do that.”

The Democratic Assembly of Wisconsin tried to force a medical commitment proposal in Cannabis, as the correction of a cratom Bill, but the Maryhuana moment said he suspects leadership He intentionally did this legislation from the agenda to avoid the show about the subject.

Meanwhile, the state income was released a tax estimate of the tax estimation since then – Estimation of the economic impact of the Sen’s economic impact. In 2023 Melissa Agard (D) by projecting that Reform would generate almost $ 170 million in case of tax revenues every year.

An estimated legislature requested by legislators Wisconsin residents spent more than $ 121 million in Illinois Canavies only In 2022, contributing $ 36 million in terms of adjacent situations.

Never and other Democrats have had at least in January The Marijuana Medical program stresses that they will be willing to taste the shelfEven if they preferred a more comprehensive reform.

Marijuana is possible with the help of readers. If you are based on journalism to defend cannabis, consider the commitment to Patreon every month.

Become patreon guard!

(Tagstotranslate) highlighted

Related Topics:
Continue Reading

Cannabis News

Cannabis operators report mixed results as rescheduling reshapes the financial outlook

Published

12 hours ago

on

May 14, 2026

By

The rescheduling came mid-quarter and rewrote the tax math for each medical sales operator, but the underlying revenue picture remained uneven in early 2026, with acquisitions driven at one end of the scale and continued top-line compression at the other.

Vireo Growth: Back on $106 million deal
Vireo Growth Inc. reported Q1 GAAP revenue of $106.2 million, up 333.5% year-over-year, driven almost entirely by recent acquisitions rather than organic growth. The company completed the Schwazze acquisition in March, adding 45 dispensaries and two manufacturing facilities in Colorado and New Mexico. At the end of the quarter, it closed Eaze and Hawthorne Gardening, FLUENT Corp. announced an acquisition agreement and executed a California dispensary joint venture with Glass House Brands. Treating all acquisitions as closed on January 1, 2025 on a pro forma basis, revenue was $210.2 million and adjusted EBITDA was $42.2 million. The company ended the quarter with $137.8 million in cash.

John Mazarakis, CEO of Vireo, said: “Performance in the first quarter met our expectations and we are excited to welcome Schwazze, Eaze and Hawthorne to Vireo. We are focused on integration and optimization across the platform, while remaining opportunistic regarding growth opportunities associated with further acquisitions.”

Cresco Labs: $151 million, 280E relief and Texas license
Cresco Labs reported Q1 revenue of $151 million, down from $165.8 million in Q1 2025. Adjusted gross margin was 50.7% and adjusted EBITDA margin of $33 million was 21.7%. Cash at the end of the quarter was $67 million against a $310 million secured term loan. The company was conditionally granted a Texas Compassionate Use Program license after the quarter ended and opened two new dispensaries in Ohio.

Management said, “Moving the state’s legal medical cannabis from Schedule I to Schedule III is the most impactful reform this industry has seen, and it validates the work we’ve been executing for years. We’ve built the operational foundation and balance sheet discipline to reap the immediate benefits of rescheduling, and position Cresco to take advantage of the broader path to normalization.”

Jushi Holdings: 4% growth, 460 basis point margin expansion
Jushi Holdings reported first-quarter revenue of $66.4 million, up 4% year-over-year, with gross profit margin up 460 basis points to 45%. Adjusted EBITDA was $11.4 million, up 17.2%. The margin improvement was driven by higher production volumes in Ohio, Massachusetts and Pennsylvania and the performance of grower processors. Jushi brand products accounted for 58% of retail revenue in vertical markets. The company refinanced $132.3 million in debt during the quarter, providing $160 million in new debt through 2029.

Jim Cacioppo, president and CEO, said: “The recent scheduling of state-licensed medical marijuana for Schedule III is an important milestone for the industry, eliminating 280E tax limitations for medical operations and supporting a more favorable long-term operating environment.” Medical sales accounted for about 60% of Jushi’s 2025 revenue, making this material relief.

iAnthus Capital: Revenue falls to $33.5 million
iAnthus Capital reported first-quarter revenue of $33.5 million, down $4.6 million from 2025’s first quarter. Gross margin was 47.5%, up 477 basis points from the 2025 quarter. The company did not provide a management comment in the press release.

Country farms: international export record, fourth consecutive quarter of net income
Village Farms International reported first quarter consolidated net sales of $50.2 million, up 27% year-over-year, with net income of $2.9 million and adjusted EBITDA of $9.9 million, up 118% year-over-year. International export sales increased 171% to a record $14.6 million, driven by demand for EU-GMP compliant products in Germany. Pure Sunfarms had the top Canadian market share in dried flowers for the 15th consecutive month. The company started planting the first half of its Delta 2 greenhouse expansion and expects its Phase II facility in the Netherlands to reach full capacity by the end of 2026, which would quadruple Dutch production.

Michael DeGiglio, President and CEO, said: “Our first quarter results reflect a strong start to the year and continued momentum in our largest markets, with adjusted EBITDA growth of 118% year-over-year, significantly outpacing revenue growth of 27%, driven by our international business and continued leadership in Canada.

Cronos Group: Record revenue, $822 million in cash
Cronos Group reported Q1 net income of $45.2 million, up 40% year-over-year and a record quarter, with net income of $15.7 million and adjusted EBITDA of $5.1 million. Israel led growth PEACE NATURALS grew 53% for ninth consecutive record quarter. In Canada, the Spinach brand took first place in vapes with a 9.8% share of the national market, and maintained its top spot in edibles at 20.8%. The company ended the quarter with $821.9 million in cash and authorized a new $50 million stock repurchase program. The deadline to close the acquisition of CanAdelaar, one of the ten licensed growers in the Dutch Controlled Cannabis Supply Chain Experiment, has been extended to September 9, 2026 to allow time for regulatory approvals.

Mike Gorenstein, chairman, president and CEO, said, “Cronos achieved net earnings and gross profit in the first quarter as we continue to execute against our unlimited product strategy and the additional supply from Cronos GrowCo’s expansion fuels the next phase of our growth.”

Org chart: Revenue down 9%, Sanity Group acquisition closes after quarter
Organigram Global reported fiscal second quarter net income of $59.8 million, down 9% year-over-year, with adjusted EBITDA of $0.9 million, down 82%. Lower vape and pre-infusion sales drove the decline, along with a $5.8 billion dent in the U.S. hemp business. The company achieved a record quarterly harvest of over 32,000kg at its Moncton facility, up 56% year-on-year, and launched 10 SKUs in Australia targeting over 4,000 pharmacies. At the end of the quarter, Organigram acquired Sanity Group, one of Germany’s leading cannabis companies, and updated its 2026 guidance to net revenue of more than $350 million.

James Yamanaka, CEO, said: “Q2 reflected our poor performance in vaporizers and temporary challenges in pre-infusion production, compounded by slower industry growth. We have acted quickly to address these issues, and the operational changes and product improvements we have implemented are already beginning to stabilize performance.”

Greg Guyatt, Chief Financial Officer, said: “The financial impact of the competitive and operational challenges encountered earlier in fiscal 2026 is believed to have materialized in the first half of the year, and we are now beginning to stabilize performance. We expect to resume a trajectory of margin expansion and improved profitability during the second half of the year, supported by positive revenue and international sales growth. The Sanity Group.”

Continue Reading

Cannabis News

Medical Marijuana Helps Pain Patients Reduce Use Of Opioids, New Study Shows

Published

12 hours ago

on

May 14, 2026

By

As opioids continue to cause overdose deaths, a new study suggests that making medical cannabis available and affordable could help patients reduce their use of prescription painkillers.

“Although cannabis has historically been characterized as a potential ‘gateway drug,’ it may also serve as a harm reduction tool for some patients seeking to reduce their reliance on higher-risk opioid medications,” researchers at the University of Pennsylvania Perelman School of Medicine found.

The study, a prospective observational trial at the Hospital of the University of Pennsylvania, followed 29 adults over five months. All had been living with chronic pain for years—an average of 11 years—and were already taking opioid medications, but struggled to taper off of them despite other treatments.

The study is unique in its focus on cost as a factor in access to medical marijuana, with the researchers describing their work as “the first prospective observational study evaluating medical cannabis as an alternative to opioids in a setting where cost was removed as a major barrier.”

Participants were recruited from a university outpatient chronic pain clinic and then completed monthly pain assessments using the Numeric Pain Rating Scale (NRS). The researchers measured daily opioid use, measured in milligrams of morphine equivalents (MME).

“Seven patients (24%) were able to completely discontinue opioid therapy at the end of the study, five of whom did so by the second month. Pain levels also decreased over time,” the authors wrote.

Notably, “there was a statistically significant reduction in mean pain scores experienced over the five-month study period,” says the paper published in the Cureus Journal of Medical Science.

“There was also a reduction in average opioid consumption of about 32 MME per day, which remained the same throughout the follow-up. In addition, seven patients were able to completely discontinue opioid therapy during the study.”

“Mean daily opioid consumption decreased from 46.8 MME/day at baseline to 16.2 MME/day at one month and remained low during the five-month follow-up period,” the researchers found.

What set the new study apart was not just the inclusion of medical cannabis, but the deliberate removal of cost as a barrier. Participants “consistently identified cost as a major barrier to initiating medical cannabis” before enrolling in the study, the document says.

Noting the novelty of the study, they added their hypothesis: “Improving access to medical cannabis will allow a subset of patients, especially those with a high cost barrier, to reduce or discontinue opioid use while maintaining adequate pain control.”

“These results suggest that medical cannabis may be a useful adjunctive therapy to reduce opioid use, relieve chronic pain, and improve health-related quality of life,” they concluded.

“The findings of this study add to the body of literature supporting the safety profile and potential therapeutic role of cannabis.”

The studies the authors are cautious in their conclusions, warning of limitations and the need for further research. “The sample size was small and derived from a single clinical site, and there was no control group.” And because “patients self-titrate cannabis products, leading to variability in dosage and frequency of use,” the findings are not standardized.

But the authors concluded that “when used under appropriate medical supervision, medical cannabis may be an effective adjunctive strategy to reduce opioid use among patients receiving long-term opioid therapy.”

This study follows a Recent research shows that using medical marijuana helps people reduce their use of other drugs, including opioids.sleep aids and antidepressants. They also experience fewer negative side effects after switching from prescription drugs to cannabis, according to a study involving more than 3,500 patients.

It also comes from behind President Donald Trump says marijuana ‘can make people feel a lot better’ and serves as a “substitute for addictive and potentially lethal opioids.”

Last month, the Trump administration announced it moving forward with federal reclassification of marijuana medicinal cannabis is classified under Schedule I to III of the Controlled Substances Act.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Livermore Falls debates cannabis licensing fees

Published

2 days ago

on

May 13, 2026

By











Existing medical cannabis licensing fees will be temporarily applied to recreational marijuana businesses, the Select Committee decided on May 5. Board members agreed 4-1 to the temporary change, as long as officials say the fees are higher than necessary and accurately reflect the town’s oversight costs.

Bryce Cobb, Livermore Falls’ code enforcement officer, plumbing inspector, health officer and E-911 dispatcher, said voters approved the amended cannabis ordinance on April 28. Cobb said the amended ordinance allows recreational marijuana businesses and the next step was to establish a fee schedule. Recreational cannabis businesses operating in town would require local licensing approval under the ordinance.

Asked if he had fee schedules from other towns to compare, Cobb said he did not. Additionally, the town’s fee schedule specifically mentions medicinal cannabis.

“So it could be medical and adult use,” Cobb said when discussing whether the existing fee structure could apply to recreational businesses.

Read more at Sun Magazine










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media